Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-06-28
2011-06-28
Moore, Susanna (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S262000
Reexamination Certificate
active
07968554
ABSTRACT:
Disclosed are novel pyrazolo[3,4-d]pyrimidine derivatives that are inhibitors of Raf kinase. These compounds and their pharmaceutically-acceptable salts and esters are anti-proliferative agents useful in the treatment or control of proliferative disorders such as solid tumors, in particular breast tumor, colon tumor, lung tumor, prostate tumor, and melanoma. Also disclosed are a composition and a unit dose formulation comprising such a compound, or a pharmaceutically-acceptable salt or ester thereof, methods for making such compounds, and methods for using such compounds, or their pharmaceutically-acceptable salts or esters, in the treatment of proliferative disorders.
REFERENCES:
patent: 5985853 (1999-11-01), Laugraud et al.
patent: 2001/0020030 (2001-09-01), Stewart et al.
patent: 2004/0097485 (2004-05-01), Burkitt et al.
patent: 2005/0020619 (2005-01-01), Betschmann et al.
patent: 2005/0026944 (2005-02-01), Betschmann et al.
patent: 2005/0043347 (2005-02-01), Betschmann et al.
patent: 2005/0256154 (2005-11-01), Luk et al.
patent: WO96/32399 (1996-10-01), None
patent: WO99/62890 (1999-12-01), None
patent: WO00/42042 (2000-07-01), None
patent: WO00/71532 (2000-11-01), None
patent: WO02/44158 (2002-06-01), None
patent: WO03/082272 (2003-10-01), None
patent: WO2004/100947 (2004-11-01), None
patent: WO2005/056562 (2005-06-01), None
patent: WO2005/121107 (2005-12-01), None
patent: WO2006/068760 (2006-06-01), None
patent: WO2006/125101 (2006-11-01), None
patent: WO2007/075554 (2007-07-01), None
Strumberg et al., Onkologie, vol. 28, pp. 101-107 (2005).
Beeram et al., J. Clin. Oncol., vol. 23, pp. 6771-6790 (2005).
Sharma et al., Cancer Res., vol. 65, pp. 2412-2421 (2005).
Ansel et al., Pharmaceutical Dosage Forms and Drug Delivery Systems, pp. 456-457 (1995).
Robins R. K., J. Am. Chem. Soc., vol. 78, p. 784 (1956).
Lyons et al., Endocrine-Related Cancer, vol. 8 pp. 219-225 (2001).
Lee et al., Current Opinion in Investigational Drugs, vol. 4(6), pp. 757-763 (2003).
Bollag et al., Current Opinion in Investigational Drugs, vol. 4(12), pp. 1436-1441 (2003).
Wilhelm, et al., Cancer Research, vol. 64, pp. 7099-7109 (2004).
Srikala et al., Mol. Cancer Ther., vol. 4(4), pp. 677-685 (2005).
Niswender et al., Journal of Biological Chem., vol. 277(32), pp. 28916-28922 (2002).
Buzko et al., Journal of Computer-Aided Molecular Design, vol. 16(2), pp. 113-127 (2002).
Bishop et al., Journal of the American Chem. Society, vol. 121(4), pp. 627-631 (1999).
Beebe et al., Cancer Research, vol. 63 , pp. 7301-7309 (2003).
ASCO Annual Meeting Poster, Preclinical Development of CP-547,632, A Novel VEGFR-2 Inhibitor for Cancer Therapy, Abstract No. 473 (2002).
American Association for Cancer Research vol. 43, San Francisco, California, p. 1082 (2002).
Avruch et al., TIBS, vol. 19, pp. 279-283 (1994).
Magnuson et al., Cancer Biology, vol. 5, pp. 247-253 (1994).
SciFinder Search, Jan. 4, 2007 (36 pgs.).
Hanke et al., The Journal of Biological Chem., vol. 271, pp. 695-701 (1996).
Donnini et al., Int. J. Cancer. vol. 120, pp. 995-1004 (2006).
Schenone et al., European Journal of Med. Chem., vol. 39, pp. 939-946 (2004).
Burchat et al., Bioorganic & Medicinal Chem. Letters., vol. 16, pp. 118-122 (2006).
Bishop et a., Nature, vol. 407, pp. 395-401 (2000).
Press Release, Bayer Pharmaceuticals Corp. & Onyx Pharmaceuticals Inc., Dec. 20, 2005 (3 pgs.).
Bartkovitz David Joseph
Chu Xin-Jie
Luk Kin-Chun
Hoffman-La Roche Inc.
Johnston George W.
Moore Susanna
Prior Kimberly J.
Rocha-Tramaloni Patricia S.
LandOfFree
Pyrazolo[3,4-d]pyrimidine derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pyrazolo[3,4-d]pyrimidine derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyrazolo[3,4-d]pyrimidine derivatives will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2651663